Download MendeleyLeveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Smil, D., Wong, J.F., Williams, E.P., Adamson, R.J., Howarth, A., McLeod, D.A., Mamai, A., Kim, S., Wilson, B.J., Kiyota, T., Aman, A., Owen, J., Poda, G., Horiuchi, K.Y., Kuznetsova, E., Ma, H., Hamblin, J.N., Cramp, S., Roberts, O.G., Edwards, A.M., Uehling, D., Al-Awar, R., Bullock, A.N., O'Meara, J.A., Isaac, M.B.(2020) J Med Chem 63: 10061-10085
- PubMed: 32787083 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.0c01199
- Primary Citation Related Structures:
6SZM - PubMed Abstract:
There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brainstem. Radiation therapy is beneficial but not curative, with the condition being uniformly fatal. Analysis of the genomic landscape surrounding DIPG has revealed that activin receptor-like kinase-2 (ALK2) constitutes a potential target for therapeutic intervention given its dysregulation in the disease. We adopted an open science approach to develop a series of potent, selective, orally bioavailable, and brain-penetrant ALK2 inhibitors based on the lead compound LDN-214117 . Modest structural changes to the C-3, C-4, and C-5 position substituents of the core pyridine ring afforded compounds M4K2009 , M4K2117 , and M4K2163 , each with a superior potency, selectivity, and/or blood-brain barrier (BBB) penetration profile. Robust in vivo pharmacokinetic (PK) properties and tolerability mark these inhibitors as advanced preclinical compounds suitable for further development and evaluation in orthotopic models of DIPG.
- Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada.
Organizational Affiliation:
